Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Cited In for PubMed (Select 10401733)

1.

Pancreatic cancer in an Asian population.

Kongkam P, Benjasupattananun P, Taytawat P, Navicharoen P, Sriuranpong V, Vajragupta L, Klaikaew N, Ridtitid W, Treeprasertsuk S, Rerknimitr R, Kullavanijaya P.

Endosc Ultrasound. 2015 Jan-Mar;4(1):56-62. doi: 10.4103/2303-9027.151361.

2.

Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.

Kim J, Lee YS, Hwang IK, Kang BK, Cho JY, Yoon YS, Han HS, Hwang JH.

J Korean Med Sci. 2015 Mar;30(3):259-63. doi: 10.3346/jkms.2015.30.3.259. Epub 2015 Feb 16.

3.

Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft.

Yin JH, Zhu XY, Shi WD, Liu LM.

BMC Complement Altern Med. 2014 Dec 13;14(1):483. doi: 10.1186/1472-6882-14-483.

4.

Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.

Mirus JE, Zhang Y, Hollingsworth MA, Solan JL, Lampe PD, Hingorani SR.

Mol Cell Proteomics. 2014 Dec;13(12):3484-96. doi: 10.1074/mcp.M113.036517. Epub 2014 Sep 15.

PMID:
25225358
5.
6.

Therapeutic options for the management of pancreatic cancer.

Rossi ML, Rehman AA, Gondi CS.

World J Gastroenterol. 2014 Aug 28;20(32):11142-59. doi: 10.3748/wjg.v20.i32.11142.

7.

Sox9: a master regulator of the pancreatic program.

Seymour PA.

Rev Diabet Stud. 2014 Spring;11(1):51-83. doi: 10.1900/RDS.2014.11.51. Epub 2014 May 10.

PMID:
25148367
8.

Profile and potential of ixabepilone in the treatment of pancreatic cancer.

Smaglo BG, Pishvaian MJ.

Drug Des Devel Ther. 2014 Jul 14;8:923-30. doi: 10.2147/DDDT.S52964. eCollection 2014.

9.

Preoperative glucose abnormalities in patients with pancreatic tumours.

Matejak-Górska MA, Durlik M, Kałuża B, Milczarczyk A, Franek E.

Prz Gastroenterol. 2014;9(2):105-8. doi: 10.5114/pg.2014.42506. Epub 2014 May 5.

10.

c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG.

World J Gastroenterol. 2014 Jul 14;20(26):8458-70. doi: 10.3748/wjg.v20.i26.8458.

11.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.

Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

12.

Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.

Tas F, Sen F, Keskin S, Kilic L, Yildiz I.

Mol Clin Oncol. 2013 Jul;1(4):788-792. Epub 2013 May 23.

13.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):837-44. doi: 10.1016/j.ijrobp.2013.12.030.

14.

Anaesthetic perioperative management of patients with pancreatic cancer.

De Pietri L, Montalti R, Begliomini B.

World J Gastroenterol. 2014 Mar 7;20(9):2304-20. doi: 10.3748/wjg.v20.i9.2304. Review.

15.

Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.

Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, Anderson MA, Shedden KA, Ruffin MT, Lubman DM.

J Proteome Res. 2014 Apr 4;13(4):1873-84. doi: 10.1021/pr400967x. Epub 2014 Mar 10.

16.

MicroRNAs in pancreatic malignancy: progress and promises.

Srivastava SK, Arora S, Singh S, Bhardwaj A, Averett C, Singh AP.

Cancer Lett. 2014 Jun 1;347(2):167-74. doi: 10.1016/j.canlet.2014.02.015. Epub 2014 Feb 20. Review.

PMID:
24561061
17.

Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer.

Fan KY, Dholakia AS, Wild AT, Su Z, Hacker-Prietz A, Kumar R, Hodgin M, Hsu CC, Le DT, De Jesus-Acosta A, Diaz LA Jr, Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM.

J Natl Compr Canc Netw. 2014 Jan;12(1):50-7.

18.

Vascular resection in pancreatic adenocarcinoma with portal or superior mesenteric vein invasion.

Pan G, Xie KL, Wu H.

World J Gastroenterol. 2013 Dec 14;19(46):8740-4. doi: 10.3748/wjg.v19.i46.8740.

19.

Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD.

Immunol Rev. 2014 Jan;257(1):145-64. doi: 10.1111/imr.12141. Review.

20.

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.

Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K, Oka M.

J Immunother. 2014 Jan;37(1):36-42. doi: 10.1097/CJI.0000000000000012.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk